Last updated: July 5, 2026

Aetna Connecticut ADHD Treatment Coverage | Klarity Health

If you have Aetna insurance in Connecticut and are considering treatment for attention-deficit/hyperactivity disorder (ADHD), understanding your potential benefits can help you make informed decisions about your care. This guide explains how Aetna plans sold in Connecticut may cover online ADHD treatment, what prior authorization rules typically apply to ADHD medications, and how Connecticut’s mental health parity law may protect your access to covered services.

Coverage varies by plan. Verify your benefits before booking. This page is for general informational purposes only and does not constitute a guarantee of coverage.

Does Aetna Cover ADHD Treatment in Connecticut?

Many Aetna plans sold in Connecticut include behavioral health benefits that may cover ADHD evaluation and treatment, including outpatient psychiatric visits, medication management, and telehealth consultations. Aetna offers several plan types in Connecticut:

• PPO and POS plans — typically allow you to see any in-network provider without a referral. ADHD evaluation and medication management visits are commonly covered as outpatient behavioral health benefits.
• HMO plans — may require a referral from your primary care physician (PCP) before you can see a specialist for ADHD. Check your plan documents to confirm whether a referral is needed.
• Access Health CT plans — Aetna participates in Connecticut’s ACA marketplace. Marketplace plans are required to include behavioral health and mental health benefits as an essential health benefit (EHB) under the Affordable Care Act.
• Medicare Advantage (MA) plans — subject to CMS rules. Mental health and behavioral health coverage is included in most MA plans, though formulary tiers and cost-sharing may differ from commercial plans.

Aetna uses CVS Caremark as its pharmacy benefit manager (PBM) for many commercial plans. This means your ADHD medication formulary, tier placements, and prior authorization requirements are generally administered through CVS Caremark’s systems.

Connecticut Mental Health Parity and ADHD

Connecticut General Statute § 38a-514b requires insurers regulated by the Connecticut Insurance Department (CID) to apply mental health and substance use disorder benefits at parity with medical/surgical benefits. Under this statute, ADHD — classified as a neurodevelopmental disorder requiring behavioral health treatment — is generally entitled to the same coverage terms as comparable medical conditions. This means:

• Aetna cannot impose more restrictive prior authorization requirements on ADHD treatment than it applies to comparable medical or surgical conditions.
• Quantitative limits (such as visit caps or day limits) for ADHD outpatient treatment must be comparable to those for medical/surgical outpatient visits.
• Connecticut’s telehealth parity statute further requires that Aetna reimburse covered telehealth ADHD visits at rates comparable to in-person visits.

If you believe Aetna has imposed coverage restrictions that violate Connecticut parity law, you can file a complaint with the CID at 1-800-203-3447 or submit a complaint online through the CID’s website.

ERISA plans: Self-funded employer plans governed by ERISA are exempt from Connecticut state insurance mandates, including CGS § 38a-514b. If your coverage comes through a self-funded employer plan, Connecticut parity law may not apply, and federal ERISA parity rules under the Mental Health Parity and Addiction Equity Act (MHPAEA) govern instead. Check your Summary Plan Description (SPD) or contact your HR department to determine whether your plan is self-funded.

Aetna ADHD Medication Formulary in Connecticut

The following reflects general Aetna/CVS Caremark formulary patterns for ADHD medications. Actual tier placement and prior authorization requirements may vary by specific plan. Always verify your plan’s formulary at CVScaremark.com or by calling the member services number on your Aetna ID card.

Generic Stimulant Medications (Tier 1–2, Prior Authorization Required)

Generic stimulant medications are the most cost-accessible option on Aetna/CVS Caremark formularies and are typically placed at Tier 1 or Tier 2. However, prior authorization is commonly required for Schedule II stimulants even at the generic tier. Medications in this category include:

• Amphetamine salts IR (generic Adderall) — Tier 1–2, PA required, Schedule II 30-day supply limit
• Amphetamine salts XR (generic Adderall XR) — Tier 1–2, PA required, Schedule II 30-day supply limit
• Methylphenidate IR (generic Ritalin) — Tier 1–2, PA required, Schedule II 30-day supply limit
• Methylphenidate ER (generic Concerta, Ritalin LA) — Tier 1–2, PA required, Schedule II 30-day supply limit
• Dextroamphetamine IR (generic Dexedrine) — Tier 1–2, PA required, Schedule II 30-day supply limit
• Dexmethylphenidate (generic Focalin) — Tier 1–2, PA required, Schedule II 30-day supply limit
• Mixed amphetamine salts ER (generic) — Tier 1–2, PA required, Schedule II 30-day supply limit

Because all Schedule II controlled substances are limited to a 30-day supply per dispensing under federal law, your provider must issue a new prescription each month. Electronic prescribing for Schedule II medications (EPCS) is permitted in Connecticut.

Brand Stimulant Medications (Tier 3–4, Prior Authorization + Step Therapy)

Brand-name stimulants are typically placed at Tier 3 or Tier 4 on Aetna/CVS Caremark formularies and generally require both prior authorization and step therapy (demonstrating a trial of a generic alternative before brand coverage is approved). Medications in this category include:

• Vyvanse (lisdexamfetamine) — Tier 3–4, PA required, step therapy (generic amphetamine salts trial typically required), Schedule II 30-day supply limit
• Adderall XR brand — Tier 3–4, PA required, step therapy (generic XR trial typically required), Schedule II 30-day supply limit
• Concerta brand — Tier 3–4, PA required, step therapy (generic methylphenidate ER trial typically required), Schedule II 30-day supply limit
• Focalin XR brand — Tier 3–4, PA required, step therapy, Schedule II 30-day supply limit
• Mydayis (triple-bead mixed amp salts, longer duration) — Tier 3–4, PA required, step therapy, Schedule II 30-day supply limit; differentiated by up to 16h duration
• Jornay PM (methylphenidate ER, evening dosing) — Tier 3–4, PA required, step therapy; evening-dose formulation for patients whose symptoms require early-morning coverage before a standard AM dose would take effect
• Azstarys (serdexmethylphenidate/dexmethylphenidate) — Tier 3–4, PA required; prodrug formulation may be considered for patients with abuse-deterrence needs or prior tolerance issues

For brand stimulant prior authorization, Aetna/CVS Caremark typically requires documentation that the patient has tried and failed (or has a clinical contraindication to) a generic stimulant at an adequate dose for an adequate duration.

Non-Stimulant Medications

Non-stimulant ADHD medications are an important alternative for patients who cannot tolerate stimulants, have a history of substance use disorder, or have ADHD symptoms alongside anxiety or tic disorders. Non-stimulants are not classified as controlled substances and are therefore not subject to the Schedule II 30-day supply limit.

• Atomoxetine (generic Strattera) — Tier 1–2; PA requirements vary by plan; non-controlled, non-stimulant SNRI mechanism; full effect typically seen after 4–6 weeks of consistent use
• Guanfacine ER (generic Intuniv) — Tier 1–2, typically no PA required; alpha-2 agonist; often used for hyperactivity and impulsivity, particularly in pediatric patients or adults who cannot use stimulants
• Clonidine ER (generic Kapvay) — Tier 1–2, typically no PA required; alpha-2 agonist; similar profile to guanfacine ER with slightly shorter duration; not a controlled substance
• Qelbree (viloxazine ER) — Tier 3–4, PA required; non-stimulant, non-controlled; differentiated from atomoxetine by SNRI + 5-HT mechanism; typically requires PA and sometimes step therapy with atomoxetine generic
• Strattera brand — Tier 3–4, step therapy (generic atomoxetine trial typically required); no clinical difference vs generic

Teladoc Health and Klarity Health

Aetna’s in-network telehealth platform is Teladoc Health, which operates independently from Klarity Health. Klarity Health is a separate telehealth provider and is not affiliated with Teladoc Health or Aetna. Whether Klarity Health providers are in-network for your specific Aetna plan depends on your plan type and network. Check your Aetna member portal or call Aetna member services to verify in-network status for any provider before scheduling.

Prior Authorization for ADHD Treatment Under Aetna Connecticut Plans

Prior authorization (PA) is a process by which Aetna reviews a prescription before approving coverage. For ADHD stimulant medications in Connecticut, PA is commonly required even for generic Tier 1–2 options. The standard PA process typically involves:

1. Your Klarity Health provider submits a PA request to Aetna/CVS Caremark including clinical documentation (diagnosis, symptoms, functional impairment, prior medication history).
2. Aetna reviews the request. Standard review typically takes 2–5 business days. An expedited (urgent) review may be available within 72 hours when a delay could seriously jeopardize your health.
3. If approved, your pharmacy can dispense the medication with your plan’s cost-sharing applied. If denied, Aetna must provide a written explanation and information about your appeal rights.

Under Connecticut parity law (CGS § 38a-514b), Aetna cannot impose PA requirements on ADHD medications that are more restrictive than those applied to comparable medical conditions. If you believe a PA denial is inconsistent with parity requirements, you have the right to request an internal appeal and, if that is denied, an independent external review.

What to Do If Aetna Denies ADHD Coverage

If Aetna denies a prior authorization request or a claim for ADHD treatment, you have several options:

• Internal appeal: Request an internal appeal from Aetna within the timeframe specified in your denial notice (typically 180 days). Submit supporting clinical documentation from your provider.
• External review: If Aetna upholds the denial after internal appeal, you may request an independent external review. Connecticut law requires insurers to participate in external review for certain coverage denials.
• CID complaint: File a complaint with the Connecticut Insurance Department at 1-800-203-3447 if you believe Aetna has violated Connecticut insurance law, including mental health parity requirements under CGS § 38a-514b.
• Access Health CT: If you purchased your plan through Access Health CT (Connecticut’s ACA marketplace), you may also contact the marketplace for assistance navigating coverage disputes.

ERISA reminder: If your plan is a self-funded employer plan, state external review laws may not apply. Federal ERISA procedures and MHPAEA protections govern your appeals process.

Klarity Health and ADHD Treatment in Connecticut

Klarity Health connects patients in Connecticut with licensed providers who specialize in ADHD evaluation and treatment via telehealth. Klarity Health’s network includes 2,000+ licensed providers across the United States, including Connecticut-licensed clinicians who can evaluate ADHD symptoms, develop a treatment plan, and manage medications including stimulants and non-stimulants where clinically appropriate and legally permitted.

Coverage for Klarity Health services through Aetna depends on your specific plan and network. Verify your benefits before booking.

Disclaimer: Coverage varies by plan. This page is for general informational purposes and does not constitute a guarantee of insurance coverage or benefits. Always verify your specific plan’s benefits, formulary, and network before scheduling an appointment or filling a prescription. Klarity Health is not affiliated with Aetna or Teladoc Health.